Hematological findings and complications of COVID-19.
Anticoagulants
/ therapeutic use
Betacoronavirus
Biomarkers
Blood Coagulation Tests
Blood Donors
/ supply & distribution
C-Reactive Protein
/ analysis
COVID-19
COVID-19 Testing
Clinical Laboratory Techniques
Coronavirus Infections
/ blood
Cytokine Release Syndrome
/ blood
Cytokines
/ blood
Disseminated Intravascular Coagulation
/ blood
Early Diagnosis
Ferritins
/ blood
Fibrin Fibrinogen Degradation Products
/ analysis
Humans
Lymphopenia
/ etiology
Meta-Analysis as Topic
Pandemics
Pneumonia, Viral
/ blood
Risk
SARS-CoV-2
Thrombophilia
/ blood
Venous Thromboembolism
/ blood
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
07
04
2020
accepted:
08
04
2020
pubmed:
14
4
2020
medline:
1
7
2020
entrez:
14
4
2020
Statut:
ppublish
Résumé
COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life-threatening disseminated intravascular coagulation (DIC), which necessitates continuous vigilance and prompt intervention. So, COVID-19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted.
Identifiants
pubmed: 32282949
doi: 10.1002/ajh.25829
pmc: PMC7262337
doi:
Substances chimiques
Anticoagulants
0
Biomarkers
0
Cytokines
0
Fibrin Fibrinogen Degradation Products
0
fibrin fragment D
0
C-Reactive Protein
9007-41-4
Ferritins
9007-73-2
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
834-847Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
J Thromb Haemost. 2013 Feb 4;:
pubmed: 23379279
Eur J Intern Med. 2012 Jul;23(5):436-41
pubmed: 22726372
Transfusion. 2020 May;60(5):908-911
pubmed: 32198754
Am J Hematol. 2020 Jun;95(6):E131-E134
pubmed: 32129508
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Clin Chim Acta. 2020 Jun;505:190-191
pubmed: 32145275
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
J Immunol. 1999 Feb 15;162(4):2154-61
pubmed: 9973490
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Blood. 2007 May 1;109(9):3812-9
pubmed: 17255361
Clin Chim Acta. 2020 Jul;506:145-148
pubmed: 32178975
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Thromb Haemost. 2020 May;120(5):876-878
pubmed: 32246450
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Chest. 2012 Feb;141(2 Suppl):e195S-e226S
pubmed: 22315261
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):529-530
pubmed: 32203680
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
N Engl J Med. 2003 May 15;348(20):1986-94
pubmed: 12682352
TH Open. 2020 Mar 13;4(1):e59-e65
pubmed: 32190813
PLoS One. 2014 May 16;9(5):e98020
pubmed: 24837009
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Clin Lab Haematol. 2005 Feb;27(1):15-20
pubmed: 15686503
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Lancet Oncol. 2020 May;21(5):619-621
pubmed: 32220659
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Blood Adv. 2018 Nov 27;2(22):3257-3291
pubmed: 30482765
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
J Thromb Haemost. 2020 May;18(5):1023-1026
pubmed: 32338827
Emerg Microbes Infect. 2020 Dec;9(1):687-690
pubmed: 32208840
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
J Thromb Haemost. 2020 Apr;18(4):786-787
pubmed: 32212240
J Immunol. 2002 Oct 15;169(8):4288-97
pubmed: 12370360
JAMA Cardiol. 2020 Jul 1;5(7):831-840
pubmed: 32219363
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
J Med Virol. 2020 Sep;92(9):1533-1541
pubmed: 32181903
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Chin Med J (Engl). 2020 Jun 5;133(11):1261-1267
pubmed: 32209890
Bone Marrow Transplant. 2020 Oct;55(10):2043-2044
pubmed: 32203269
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120
pubmed: 32172226
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758